HAVCR2 and cancer: ICB that target other immune checkpoints (eg, lymphocyte activating gene-3 (LAG-3), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), T-cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT)), have been assessed in preclinical studies and are currently being trialed in patients across many cancer types.1 2 However, the effects of anti-TIM-3, anti-LAG-3 or anti-TIGIT ICB in combination with traditional anticancer treatment modalities such as chemotherapy remain unclear.